From Research at med.fsu.edu Tue Aug 4 09:50:47 2020 From: Research at med.fsu.edu (Med Research) Date: Tue, 4 Aug 2020 13:50:47 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16FD2C0@FSUCOM128.med.ad.fsu.edu> American Occupational Therapy Foundation: Health Services Research Grants Program The American Occupational Therapy Foundation awards Health Services Research Grants as part of its mission to advance the science of occupational therapy to support people's full participation in meaningful life activities. Health Services Research (HSR) examines how people get access to health care, how and what care is delivered, the cost of that care, and what happens to patients as a result of receiving or not receiving care. Specifically, HSR is a multidisciplinary field that studies how social factors, financing systems, organizational structures and processes, health technologies, and personal behaviors affect access to health care, the quality and costs of health care, and ultimately, the health and well-being of health care consumers. Health Services Research has a high value to both individuals and society. Past research has yielded information on intervention trends and risk factors, outcome of treatments, and patterns of care. It has established new health policies, led to significant discoveries, and to the development of new therapies. HSR Pilot Study Option #1: Includes pilot studies examining an occupational therapy-related question using data from administrative or healthcare dataset(s) (e.g. Medicare Administrative data, Health System Electronic Medical records). Funding Required: $100,000 per grant. These studies may run up to 2 years. HSR Pilot Study Option #2: Includes pilot studies examining a rehabilitation question using data from publicly available datasets (e.g., Health and Retirement Survey, National Health and Aging Trends Study, National Health and Nutrition Examination Survey, LTCFocus). Funding Required: $50,000 per grant. These studies may run up to 1 year. Letter of intent due August 31, 2020. Med-RA deadline to receive draft documents: August 18. Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications for the treatment of many diseases, disorders, and conditions. Given the emphasis on innovation, little or no preliminary data are needed to apply under this FOA. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide support for further mechanistic investigations in human subjects or animal models, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61. Due October 2, 2020; June 2, 2021; October 4, 2021; June 2, 2022; October 3, 2022; and June 02, 2023. Med-RA deadline to receive draft documents for October 2 due date: September 21. Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 / R01 Clinical Trials Not Allowed) R21 R01 Through these funding opportunity announcements, the National Cancer Institute along with the National Human Genome Research Institute and National Institute of Dental and Craniofacial Research encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 5 R01 standard date: September 22. Med-RA deadline to receive draft documents for October 16 R21 standard date: October 5. Fertility Status as a Marker for Overall Health (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these funding opportunities is to support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. Advancing this premise will require substantive involvement of experts in reproductive health/fertility along with expert in another non-reproductive specialty appropriate to the area of overall health being investigated, for example, in other fields such as epidemiology, or the somatic disease in question. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of the disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA. Due October 19, 2020; June 19, 2021; February 19, 2022; October 19, 2022; and June 19, 2023. Med-RA deadline to receive draft documents for October 19 due date: October 6. Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R03 / R21 / R01 Clinical Trial Optional) R03 R21 R01 These Funding Opportunity Announcements invite applications that propose to study the ethical, legal and social implications of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. Due October 19, 2020; February, 17 2021; June 17, 2021; October 19, 2021; February 17, 2022; June 17, 2022; October 19, 2022; February 17, 2023; and June 19, 2023. Med-RA deadline to receive draft documents for October 19 due date: October 6. Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement, the National Cancer Institute and the National Institute on Aging will promote research to advance the understanding of the mechanistic factors and cellular interactions during aging that contribute to cancer initiation. Collaborations are strongly encouraged between scientists in the fields of aging biology and cancer biology. Applications should address key questions regarding how hallmarks of aging that lead to impaired cellular activities (metabolic alterations, proteostasis, epigenetic changes, and DNA repair) and alterations in the microenvironment (inflammation and immunosenescence) contribute to the development and outgrowth of cancer-initiating cells. Due October 27, 2020 and February 17, 2021. Med-RA deadline to receive draft documents for October 27 due date: October 14. Biogen Medical Education, Patient Education, and Professional & Scientific Development Grants Biogen considers requests across a variety of disease areas including: Alzheimer?s Disease, Amyotrophic Lateral Sclerosis, Lupus, Multiple Sclerosis, Ophthalmology, Parkinson?s Disease, and Spinal Muscular Atrophy. Medical Education Funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited. Patient Education Funding to an eligible institution or organization to support independent educational activities for patients or caregivers. Professional & Scientific Development Financial contribution to provide training and development for medical professionals or researchers within Biogen?s therapeutic areas of interest. November 1, 2020; February 15, 2021; and May 15, 2021. Med-RA deadline to receive draft documents for November 1 due date: October 20. Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional) This Funding Opportunity Announcement invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions. Due November 10, 2020. Med-RA deadline to receive draft documents: October 28. Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device. Due December 15, 2020; August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; and August 10, 2023. Med-RA deadline to receive draft documents for December 15 due date: December 2. Elsa U. Pardee Foundation: Cancer Research Grants The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Due December 31, 2020, April 30, 2021, August 31, 2021. Med-RA deadline to receive draft documents for December 31 due date: December 14. Congressionally Directed Medical Research Programs Combat Readiness ? Medical Research Program Rapid Development and Translational Research Award Pre-application (preproposal): September 10, 2020. Application: December 3, 2020. Med-RA deadline to receive draft documents for preproposal due date: August 31. Scleroderma Research Program Idea Development Award Pre-application (preproposal): September 9, 2020. Application: December 4, 2020. Translational Research Partnership Award Pre-application (preproposal): September 9, 2020. Application: December 4, 2020. Med-RA deadline to receive draft documents for preproposal due date: August 31. Forecast Reducing Inequities in Cancer Outcomes through Community-Based Interventions on Social Determinants of Health Estimated post date: December 2, 2020 Anticipated due date: February 10, 2021 The purpose of this CDC-ERA competition is to conduct evaluation research to build an evidence base of innovative, community-based interventions across multiple domains of social determinants of health to reduce racial and ethnic disparities in cancer outcomes. Evaluation research is defined as the systematic application of public health research procedures for assessing the conceptualization, design, implementation, effectiveness and utility of public health interventions. This research would advance our understanding of what works, for whom and why. Component A: Primary Cancer Prevention ? to conduct evaluation research on an innovative, multi-sector intervention to reduce cancer risk in one or more socially or economically disadvantaged populations. This research will examine the implementation, impact, and causal mechanisms of the intervention?s effect to reduce cancer risk at the population level. Component B: Cancer Screening ? to conduct evaluation research on an innovative, multi-sector intervention to reduce inequities in the receipt of appropriate screening services (on-time initial screening, routine re-screening at recommended intervals, appropriate follow-up after inconclusive/incomplete screening) among one or more socially or economically disadvantaged populations. This research will generate knowledge about the implementation, impact, and causal mechanisms of the intervention?s effect on cancer screening outcomes. Component C: Health and Wellbeing of Cancer Survivors ? to conduct evaluation research on an innovative, multi-sector intervention to address barriers to health and well-being among cancer survivors from one or more socially or economically disadvantaged populations. This research will generate knowledge about the implementation, impact, and causal mechanisms of the intervention?s effect on the health and wellbeing of cancer survivors. Applicants may apply for one Component (Component A or Component B or Component C). To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Tue Aug 4 14:52:37 2020 From: Research at med.fsu.edu (Med Research) Date: Tue, 4 Aug 2020 18:52:37 +0000 Subject: Limited Submission first-come first-nominated: Kleberg Foundation In-Reply-To: <978C7BCD-59D7-43C9-9B6F-06369471F3B9@med.fsu.edu> References: <978C7BCD-59D7-43C9-9B6F-06369471F3B9@med.fsu.edu> Message-ID: <678887EBDC79FB438BFD062B064C59A401A16FE0C3@FSUCOM128.med.ad.fsu.edu> The internal deadline for the Kleberg Foundation Medical Research Grants competition has passed, and therefore the first researchers to claim FSU?s spot will get this Limited Submission nomination. To claim the nomination and submit the application on September 30, go to https://www.research.fsu.edu/limitedsubmission/, locate the Kleberg Foundation entry, and then use the ?contact OPD? email button (and please cc research at med.fsu.edu). The Foundation is seeking highly innovative and groundbreaking medical research proposals from top tier institutions in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health. Proposals should be distinctive and novel in their approaches, question the prevailing paradigm, and lead to advancement of knowledge in the field. A highly qualified scientific advisory committee will review all proposals. Award amounts range from approximately $300,000?$1,000,000 for projects of 1?3 years, no IDC. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Aug 17 11:58:00 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 17 Aug 2020 15:58:00 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A1701F6D@FSUCOM128.med.ad.fsu.edu> FSU Council on Research and Creativity Committee on Faculty Research Support (COFRS) Program Pre-review deadline: November 30, 2020, 4:59 p.m. Due December 10, 2020. Med-RA deadline to receive draft documents: November 30. Equipment & Infrastructure Enhancement (EIEG) Program Pre-review deadlines: September 21, 2020, 4:59 p.m. and March 1, 2021, 4:59 p.m. Due October 1, 2020 and March 11, 2021. Med-RA deadline to receive draft documents for October 1 due date: September 21. First Year Assistant Professor (FYAP) Program FYAP Workshop: September 11, 2020 (mandatory for submitters). Pre-review deadline: October 12, 2020, 4:59 p.m. Due October 22, 2020. Med-RA deadline to receive draft documents: October 12. Multidisciplinary Support (MDS) Program Pre-review deadline: November 9, 2020, 4:59 p.m. Due November 19, 2020. Med-RA deadline to receive draft documents: November 9. Planning Grant (PG) Program Pre-review deadlines: September 21, 2020, 4:59 p.m. and March 1, 2021, 4:59 p.m. Due October 1, 2020 and March 11, 2021. Med-RA deadline to receive draft documents for October 1 due date: September 21. Small Grants Program (SGP) Pre-review deadlines: September 28, 2020, 4:59 p.m. and March 8, 2021, 4:59 p.m. Due October 8, 2020 and March 18, 2021. Med-RA deadline to receive draft documents for October 8 due date: September 28. William T. Grant Foundation: Institutional Challenge Grant The Institutional Challenge Grant encourages university-based research institutes, schools, and centers to build sustained research-practice partnerships with public agencies or nonprofit organizations in order to reduce inequality in youth outcomes. To do so, research institutions will need to shift their policies and practices to value collaborative research. They will also need to build the capacity of researchers to produce relevant work and the capacity of agency and nonprofit partners to use research. Applications are welcome from partnerships in youth-serving areas such as education, justice, child welfare, mental health, immigration, and workforce development. We especially encourage proposals from teams with African American, Latino, Native American, and Asian American members in leadership roles. The partnership leadership team should include the principal investigator from the research institution and the lead from the public agency or nonprofit organization. Up to $650,000 over three years. Due September 10, 2020. Med-RA deadline to receive draft documents: August 27. American Cancer Society / Pfizer: Addressing Racial Disparities in Cancer Care Through the program, grants will be awarded in support of quality improvement projects with the potential to reduce systemic barriers and address disparities in the delivery of cancer care impacting outcomes for black men and women facing cancer. Projects with the greatest likelihood to directly impact patient care for black patients across multiple cancer types and those that can be scaled or replicated will be given priority. The intent of the collaboration is to support proposals that address systemic disparities along the continuum of cancer care. Example project proposal topics include screening; diagnosis; treatment selection; treatment outcomes; clinical trials participation; access to care (e.g., social support, navigation, geographic barriers); socioeconomic barriers; age-related barriers (e.g., under-treatment of older people); management of co-morbidities; and delays in diagnosis, treatment, and/or healthcare delivery. The RFP seeks to support quality improvement initiatives, not clinical or health services research projects. Grants of up to $400,000 (inclusive of both direct and indirect costs) over two years will be awarded. The total available budget related to this RFP is approximately $2 million. Due September 10, 2020. Med-RA deadline to receive draft documents: August 27. Center for Sharing Public Health Services: Small Grants Program The Center for Sharing Public Health Services (the ?Center?) is offering small grants to support work on cross-jurisdictional sharing (CJS) arrangements designed to advance health equity by addressing social determinants of health (e.g., affordable housing, jobs with fair pay, quality education, affordable healthy food and public safety), the public health response to COVID-19, structural racism or other related issues. Up to 5 awards will be made for an amount of up to $10,000 for a project period of up to eight months. Shorter projects will be considered. All projects must be concluded by June 11, 2021. In addition to funding, Center staff will provide technical assistance tailored to each grantee?s needs. Grantees are expected to share the progress of their efforts during the project period, share results and lessons learned at the end of the project period and share longer-term activities and results 12 months after the project period ends. Project Classifications: (1) Specific CJS arrangement or (2) Use of CJS as a systems change tool. Due September 11, 2020. Med-RA deadline to receive draft documents: August 31. Scleroderma Foundation: New and Established Investigator Grant Programs The Scleroderma Foundation seeks applications from promising new and established investigators both inside and outside the field of scleroderma research who wish to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to the disease. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal or non-federal sources. New Investigator: 3 year projects; $50,000 per year; 8% IDC. Established Investigator: 2 year projects; $75,000 per year; 8% IDC. Due September 15, 2020. Med-RA deadline to receive draft documents: September 1. Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional) The goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. Due September 15, 2020. Med-RA deadline to receive draft documents: September 1. Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed) This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise. Due September 15, 2020. Med-RA deadline to receive draft documents: September 1. Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed) This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. Due September 18, 2020. Med-RA deadline to receive draft documents: September 8. Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Due September 30, 2020. Med-RA deadline to receive draft documents: September 17. Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional) This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. Due September 30, 2020. Med-RA deadline to receive draft documents: September 17. NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role). Due September 14, 2020; January 12, 2021; May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; and May 12, 2023. Med-RA deadline to receive draft documents for September 14 due date: September 1. Cellular and Molecular Biology of Complex Brain Disorders (R21 / R01 Clinical Trial Not Allowed) R21 R01 These Funding Opportunity Announcements (FOAs) encourage research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of these FOAs, the term ?complex? can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to ?model? disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. Standard dates apply. Expires September 8, 2023. Med-RA deadline to receive draft documents for October 5 R01 standard date: September 22. Med-RA deadline to receive draft documents for October 16 R21 standard date: October 5. Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed) Accumulation of abnormal proteins such as alpha-synuclein or tau in the brains of patients with dementia tends to occur in specific brain structures (cells/circuits/regions), resulting in the unique clinical presentations that are characteristic of the different types of dementia. This funding opportunity announcement invites applications that seek to identify mechanisms responsible for this selective regional vulnerability to abnormal protein deposition in the brains of patients with Lewy Body Dementia or Frontotemporal Dementia. Due October 27, 2020. Med-RA deadline to receive draft documents: October 14. Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed) This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanism of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest. Due October 27, 2020. Med-RA deadline to receive draft documents: October 14. NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) The NIAID New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome. Due November 2, 2020; October 14, 2021; and October 14, 2022. Med-RA deadline to receive draft documents for November 2 due date: October 20. Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. Due November 4, 2020; May 6, 2021; November 4, 2021; May 5, 2021; November 3, 3022; and May 4, 2023. Med-RA deadline to receive draft documents for November 4 due date: October 22. Systematic Characterization of Genomic Variation on Genome Function and Phenotype (UM1 Clinical Trial Not Allowed) This FOA seeks applications to experimentally correlate genomic variants with their effects on genomic function. This will be accomplished by performing systematic perturbation; collecting data on the effects of non-coding and protein-coding genomic variation on molecular, cellular, and organismal phenotypes; generating a catalog of these variant effects; and assisting in a group predictive modeling effort using the data. This will also be accomplished by enabling others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function (IGVF) Consortium. As members of this Consortium, functional characterization centers will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses. Due November 4, 2020. Med-RA deadline to receive draft documents: October 22. Defining Genomic Influence on Gene Network Regulation (U01 Clinical Trial Not Allowed) This FOA seeks applications for research projects to explore the effects of genomic variation on phenotypes at the network level. Research projects supported through this FOA will measure changes in the activity of genes and regulatory elements during biological transitions and use generalizable analytical approaches to understand network-level relationships among genomic variation, functional elements, genes, and phenotypes related to human health and disease. Funded projects will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, network projects will be expected to work with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease. Due November 4, 2020. Med-RA deadline to receive draft documents: October 22. Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function (UM1 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to establish Mapping Centers that will generate single-cell, multi-omic maps of genes and regulatory elements in the human and mouse genomes. This will be accomplished through use of high-throughput state-of-the-art methods to profile biochemical features characteristic of genomic elements while preserving information about biological and/or spatial context. As a group, Mapping Centers will be expected to pursue studies that will provide a range of data types that will best enable the association of gene and regulatory element activity with specific cell fates and states. Mapping Centers will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this consortium, Mapping Centers will be expected to work closely with one another and other consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses. Due November 4, 2020. Med-RA deadline to receive draft documents: October 22. Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial Not Allowed) This FOA seeks applications for Predictive Modeling Projects that will develop and apply innovative computational models to predict the impact of genomic variation on genome function and/or phenotype and generate a catalog of variant effects. Projects will also enable others to perform related research by sharing approaches and standards and by identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, predictive modeling projects will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease. Due November 4, 2020. Med-RA deadline to receive draft documents: October 22. Congressionally Directed Medical Research Programs Rare Cancers Research Program Concept Award Pre-application (letter of intent): November 12, 2020. Application: November 30, 2020. Idea Development Award Pre-application (letter of intent): November 12, 2020. Application: November 30, 2020. Resource and Community Development Award Pre-application (letter of intent): November 12, 2020. Application: November 30, 2020. Med-RA deadline to receive draft documents for application due date: November 16. NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) The NIDDK Catalyst Award is designed to complement NIDDK?s traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK?s Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK?s Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator?s research program or elsewhere. Due January 6, 2021. Med-RA deadline to receive draft documents: December 14. Forecasts Addressing Racial and Ethnic Disparities to Improve Health Outcomes The HHS Office of Minority Health is offering funding to support State and local collaborative teams in implementing a methodological framework and strategies for assessing and addressing structural racism in health policies, developed through a complementary policy academy initiative. In particular, awardees will: (1) Obtain governmental and public buy-in for engaging in this policy collaborative endeavor; (2) Create a multi-sector team (e.g., comprised of leadership from the governor's/mayor's office and health, behavioral health, child welfare, justice, education, commerce, community service and other agencies, and from community organizations); (3) Conduct a review of existing policies to identify the areas primed for a structural racism assessment; (4) Develop or revise a policy (or policies) to address structural racism and improve health outcomes; (5) Implement the new/revised policy and evaluate its impact on health outcomes for racial and ethnic minorities within their jurisdiction; and (6) Create and implement strategies to communicate, sustain and spread policies resulting in improved health outcomes for racial and ethnic minorities. BACKGROUND: Racial and ethnic minority populations experience a number of disparities which contribute to poor health outcomes. Structural racism, evidenced in residential segregation, inequitable allocation and quality of services and resources such as health care and education, disproportionate contact with the justice system, and lack of access to employment opportunities, plays a persistent and large role in historical disadvantage and supports the persistence of racial and ethnic health disparities. Estimated post date: December 31, 2020. Estimated application deadline: March 31, 2020. Family-Centered Approaches to Improving Type 2 Diabetes Control and Prevention The HHS Office of Minority Health will offer funding for an initiative to test and disseminate models/protocols that use a theoretically-based family-centered approach to promote the management and prevention of Type 2 diabetes in adults. Implementation of models/protocols may be delivered by and/or with the assistance of community health workers and/or community-based organizations to ensure cultural and linguistically appropriate delivery of services and sustainability. Funded projects will employ a strong theoretical framework to foster replicability, specifying community factors and resources that enable sustainability. Models/protocols will: (1) Describe the roles of family in the intervention, provide detailed family-based topics to be embedded in interventions, assess the quality and extent of family participation necessary for positive diabetes markers and health outcomes for persons with diabetes and family members; (2) Delineate how the model(s) takes into account and is (are) tailored to cultural factors/Social Determinants Of Health that may affect the adoption of self-management activities and behaviors associated with diabetes prevention; and (3) Identify lifestyle modifications and community supports (e.g., sustainable resources/institutions for physical activity and nutrition) that build and reinforce behavioral changes conducive to diabetes control and prevention that may be strengthened through reciprocal influence. BACKGROUND: This initiative is based on well documented racial and ethnic disparities in diabetes. According to the National Diabetes Statistics Report, 2020 (CDC, 2020) prevalence of diagnosed diabetes is highest among American Indians/Alaska Natives (14.7%), people of Hispanic origin (12.5%), and non- Hispanic blacks (11.7%), followed by non-Hispanic Asians (9.2%) and non-Hispanic whites (7.5%). Involving family members in diabetes self-care and prevention interventions is thought to positively influence patients' diabetes outcomes. However, it is unclear how family involvement operates in Type 2 diabetes interventions and what factors can best affect patient and family members' health outcomes in different racial and ethnic communities. Estimated post date: November 15, 2020. Estimated application deadline: February 15, 2021. Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study The purpose of this Notice is to alert the community that NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL) Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. This Notice is being provided to allow potential applicants sufficient time to form meaningful collaborations and develop responsive applications. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The study will comprise a normative sample that represents the diversity of pregnant women in the US population, a cohort of women who have used opioids and other substances during pregnancy will also be recruited, and a comparison group from similar backgrounds/environments as the cohort of women who have used substances. The study is intended to create a well-characterized cohort of children in order to examine the developmental impact of pre/postnatal drug exposure and multiple other genetic and environmental factors that affect risk or resilience in various health and mental health domains. Anonymized data from this cohort will be made available to the broader research community during the course of the study to maximize their utility. Estimated post date: November 1, 2020. Estimated application deadline: March 1, 2021. Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Project (U01 Clinical Trial Optional) The National Institute on Alcohol Abuse and Alcoholism intends to renew an initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for collaborative research projects (U01) to investigate brain mechanisms of excessive alcohol drinking and related phenotypes associated with alcohol use disorder (AUD). The U01s are components of a Consortium on the Integrative Neuroscience Initiative on Alcoholism (INIA). Estimated post date: October 15, 2020. Estimated application deadline: May 18, 2021. Emerging Issues in Maternal and Child Health To address emerging issues in maternal and child health. Estimated post date: January 9, 2021. Estimated application deadline: April 9, 2021. Maternal and Child Health Leadership, Education, and Advancement in Undergraduate Pathways (LEAP) Training Program The purpose of the Maternal and Child Health Pipeline Training Program is to promote the development of a culturally diverse and representative health care workforce by recruiting undergraduate training students from economically and educationally disadvantaged backgrounds (including racial and ethnic minorities) into maternal and child health professions. Estimated post date: October 8, 2020. Estimated application deadline: January 6, 2021. Rapid Response Rural Data Analysis and Issue Specific Rural Research Studies The purpose of this program is to assist rural communities with conducting rapid data analyses and short term issue-specific rural research studies to understand the impact of current and proposed policies and regulations as well as provide information that will improve access to health care and population health in rural America. Due to the nature of rural policy analysis and formulation, rural organizations and health care providers often require timely information that is available only through specialized analysis of databases of information compiled by the Centers for Medicare & Medicaid Services (CMS), other federal and state agencies, or private organizations. The awardee is responsible for collaborating with HHS agencies to compile and analyze the data that is requested in a timely manner. The awardee will also collaborate with rural stakeholders to determine what data sets are needed. These collaborative efforts are vital as most rural groups and individuals do not have the capacity to store the data sets, the staff expertise to refine and analyze the data nor the technology necessary to run statistical analyses. Estimated post date: November 30, 2020. Estimated application deadline: January 29, 2021. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Aug 28 08:36:28 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 28 Aug 2020 12:36:28 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A1704247@FSUCOM128.med.ad.fsu.edu> Guggenheim Fellowship Established in 1925 by former U.S. senator Simon Guggenheim and his wife in memory of their son, John Simon, who died in 1922 at the age of 17, the foundation has sought from its inception to ?add to the educational, literary, artistic, and scientific power of this country, and also to provide for the cause of better international understanding.? To that end, the foundation awards approximately 175 fellowships annually to professionals who have already demonstrated exceptional capacity for productive scholarship or creativity in the arts. Fellowships are awarded for a minimum of six months and a maximum of twelve months, with the goal of providing recipients with blocks of time in which they can work with as much creative freedom as possible. The fellowship is open to writers, scholars, or scientists with a significant record of publication, as well as artists, playwrights, filmmakers, photographers, composers, and others with a significant record of exhibition or performance of their work. Note: Among the 2020 Fellows, there are several in the fields of Biochemistry and Molecular Biology. Due September 17, 2020. Med-RA deadline to receive draft documents: September 8. Amyloidosis Foundation Research Grants The Amyloidosis Foundation is committed to serving patient needs by supporting basic and clinical research and providing annual grants to junior research scientists whose research targets the challenges in the field of amyloidosis. To that end, the foundation welcomes applications from early-career research scientists for its Research Grants program. Through the program, grants of up to $50,000 will be awarded to the recipient's sponsoring institution, in two disbursements, with the second payment contingent on a mid-year update report. Upon request, a second year of funding will be considered, pending review of the research progress and as foundation funding permits. To be eligible, applicants must be within ten years of completion of postdoctoral studies or clinical fellowship and must have a mentor to guarantee that the research environment will support the applicant's research project. Due September 21, 2020. Med-RA deadline to receive draft documents: September 8. Greenwall Foundation: Faculty Scholars Program in Bioethics The Greenwall Faculty Scholars Program in Bioethics is a career development award to enable junior faculty members to carry out innovative bioethics research. It supports research that goes beyond current work in bioethics to help resolve pressing ethical issues in clinical, biomedical, and public health decision-making, policy, and practice, and creates a community that enhances future bioethics research by Scholars and Alumni/ae. Each year, the Foundation selects approximately three Greenwall Faculty Scholars to receive 50 percent salary support for three years to enable them to carry out a specific research proposal and develop their research program. Letter of intent due September 21, 2020. Med-RA deadline to receive draft documents: September 8. CASE Fred Morgan Kirby Prize for Scaling Social Impact The Fred Morgan Kirby Prize for Scaling Social Impact is an annual global prize of $100,000 USD in unrestricted funds that amplifies and accelerates the work of enterprises working to scale their impact on social or environmental problems around the world. The F. M. Kirby Impact Prize is open to all impact enterprises, working anywhere in the world, that meet the following criteria: * Any nonprofit or for-profit social enterprise working anywhere in the world * Enterprise has strong evidence of impact over at least 3 years and has a plan for how to use the prize to scale that impact in the next 3-5 years * The enterprise has a robust non-discrimination policy that protects against discrimination on the basis of race, religion, national origin, sexual orientation, age, and disability* * Has exemplary leadership that aligns with the core values of Fred Morgan Kirby, including integrity, resourcefulness, resilience, meaningful collaboration and diversity Due September 30, 2020. Med-RA deadline to receive draft documents: September 17. NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. Due October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; and June 21, 2022. Med-RA deadline to receive draft documents for the October 20, 2020 due date: October 7. NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed) This Funding Opportunity Announcement solicits resource grant applications for projects that will bring useful, usable health information to health disparity populations and their health care providers. Access to useful, usable, understandable health information is an important factor when making health decisions. Proposed projects should exploit the capabilities of computer and information technology and health sciences libraries to bring health-related information to consumers and their health care providers. Due October 23, 2020; October 22, 2021; and October 21, 2022. Med-RA deadline to receive draft documents for the October 23, 2020 due date: October 12. Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel as Recommendation J, the development of New Enabling Cancer Technologies. The purpose of this FOA is to stimulate the development of new cancer data visualization methods and tools that have the potential to make data aligned with the Cancer Moonshot more explorable and interpretable by the broader cancer research community. This FOA supports the development of new, full-featured data visualization tools for investigator-specified, Moonshot-aligned use cases that enable a broader community of users to explore and gain insights from data emerging from or aligned with one or more of the Cancer Moonshot areas. Due October 30, 2020. Med-RA deadline to receive draft documents: October 19. NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) The NIAID New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome. Due November 2, 2020; October 14, 2021; and October 14, 2022. Med-RA deadline to receive draft documents for November 2, 2020 due date: October 20. NSF Biology Integration Institutes Biology has transformed science over the last century through discoveries that cross subdisciplines from the molecular to the organismal to the ecosystem level. While making great progress, biology has also slowly fragmented into subdisciplines, creating a dynamic tension between unifying principles and increasingly reductionist pursuits. The aim of this solicitation is to bring researchers together around the common goal of understanding how the processes that sustain life and enable biological innovation operate and interact within and across different scales of organization, from molecules to cells, tissues to organisms, species, ecosystems, biomes and the entire Earth. The Biology Integration Institutes program supports collaborative teams of researchers investigating questions that span multiple disciplines within and beyond biology. Integration across biological disciplines is essential if we hope to understand the diverse and ever-increasing data streams of modern biology and tackle emergent questions about living organisms and the environment. Of equal importance is the need for groundbreaking and sustainable training programs that prepare the next generations of scientists to navigate the breadth of biological sciences, training in multiple disciplines without sacrificing depth of learning or innovation. In addition, the biology community must continue to develop practices and adopt strategies that leverage rapid advances in cyberinfrastructure and other technologies to bridge and integrate across subdisciplines and make resources accessible, re-usable, and adaptable for unanticipated purposes. In these ways, Biology Integration Institutes will focus on biological themes that enable the discoveries of life?s innovations. The outcomes from biological integration will inspire new biotechnologies and applications to drive our bioeconomy and provide solutions to societal challenges. While this solicitation focuses on the integration of biological subdisciplines, any field beyond biology may be included as needed to address the overarching biological theme. Due January 13, 2021. Med-RA deadline to receive draft documents: January 4. Disseminating and Implementing Patient-Centered Outcomes Research (PCOR) Evidence into Practice through Interoperable Clinical Decision Support (R18) This Funding Opportunity Announcement invites R18 grant applications that disseminate and implement patient-centered outcomes research evidence in clinical practice by scaling computer-based, interoperable clinical decision support. Standard dates apply. Expires January 26, 2022. Med-RA deadline to receive draft documents for January 25, 2021 standard date: January 11. RESolution of InflammaTion in EnvirOnmentally Related diseasE (RESTORE) (R01 Clinical Trial Not Allowed) The purpose of the RESTORE program is to advance understanding of the role of inflammation resolution pathways at the cellular and molecular level and how exposure to environmental pollutants interferes with these pathways resulting in exposure-induced chronic systemic inflammation and ultimately chronic disease conditions. The initial phase of this program is focused on understanding how chronic exposure to air pollution interferes with resolution of inflammation in pulmonary, cardiovascular, and metabolic systems and diseases. Due February 11, 2021. Med-RA deadline to receive draft documents: February 1. Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them. Due March 3, 2021 and November 17, 2021. Med-RA deadline to receive draft documents for the March 3, 2021 due date: February 18. NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective. Due March 31, 2021. Med-RA deadline to receive draft documents: March 18. Forecasts Addressing Racial and Ethnic Disparities to Improve Health Outcomes The HHS Office of Minority Health is offering funding to support State and local collaborative teams in implementing a methodological framework and strategies for assessing and addressing structural racism in health policies, developed through a complementary policy academy initiative. In particular, awardees will: (1) Obtain governmental and public buy-in for engaging in this policy collaborative endeavor; (2) Create a multi-sector team (e.g., comprised of leadership from the governor's/mayor's office and health, behavioral health, child welfare, justice, education, commerce, community service and other agencies, and from community organizations); (3) Conduct a review of existing policies to identify the areas primed for a structural racism assessment; (4) Develop or revise a policy (or policies) to address structural racism and improve health outcomes; (5) Implement the new/revised policy and evaluate its impact on health outcomes for racial and ethnic minorities within their jurisdiction; and (6) Create and implement strategies to communicate, sustain and spread policies resulting in improved health outcomes for racial and ethnic minorities. BACKGROUND: Racial and ethnic minority populations experience a number of disparities which contribute to poor health outcomes. Structural racism, evidenced in residential segregation, inequitable allocation and quality of services and resources such as health care and education, disproportionate contact with the justice system, and lack of access to employment opportunities, plays a persistent and large role in historical disadvantage and supports the persistence of racial and ethnic health disparities. Estimated post date: December 31, 2020 Estimated due date: March 31, 2021 To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: